|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
139,229 |
182,993 |
316,353 |
613,922 |
Total Sell Value |
$12,316,080 |
$16,513,389 |
$28,948,007 |
$58,289,822 |
Total People Sold |
5 |
5 |
6 |
8 |
Total Sell Transactions |
11 |
15 |
24 |
55 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
39,600 |
254,757 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2015-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
9,600 |
73,846 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2015-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
10,500 |
42,090 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2015-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
13,400 |
89,950 |
|
- |
|
Baffi Robert |
EVP, Technical Operations |
|
2015-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
10,500 |
109,700 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2015-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
10,500 |
79,278 |
|
- |
|
Lapalme Pierre |
Director |
|
2015-03-03 |
4 |
S |
$106.57 |
$2,131,400 |
D/D |
(20,000) |
30,150 |
|
- |
|
Lapalme Pierre |
Director |
|
2015-03-03 |
4 |
OE |
$11.15 |
$284,800 |
D/D |
20,000 |
50,150 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2015-03-03 |
4 |
S |
$109.46 |
$766,210 |
D/D |
(7,000) |
8,800 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2015-03-03 |
4 |
OE |
$28.23 |
$197,610 |
D/D |
7,000 |
15,800 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-03-03 |
4 |
AS |
$107.42 |
$537,097 |
D/D |
(5,000) |
215,157 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2015-03-02 |
4 |
S |
$107.00 |
$1,658,500 |
D/D |
(15,500) |
68,676 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2015-03-02 |
4 |
OE |
$39.06 |
$605,430 |
D/D |
15,500 |
84,176 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2015-03-02 |
4 |
S |
$108.31 |
$2,491,027 |
D/D |
(23,000) |
64,246 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2015-03-02 |
4 |
OE |
$26.49 |
$609,270 |
D/D |
23,000 |
87,246 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-03-02 |
4 |
AS |
$108.44 |
$542,195 |
D/D |
(5,000) |
220,157 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-03-02 |
4 |
AS |
$107.96 |
$323,893 |
I/I |
(3,000) |
43,195 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-03-02 |
4 |
OE |
$12.99 |
$38,970 |
I/I |
3,000 |
46,195 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2015-01-16 |
5 |
GD |
$0.00 |
$0 |
D/D |
75 |
66,081 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2015-01-09 |
4 |
AS |
$94.14 |
$188,286 |
D/D |
(2,000) |
225,157 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-12-24 |
4 |
AS |
$88.73 |
$177,462 |
D/D |
(2,000) |
227,157 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-12-24 |
4 |
AS |
$88.73 |
$266,193 |
I/I |
(3,000) |
43,195 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-12-24 |
4 |
OE |
$12.99 |
$38,970 |
I/I |
3,000 |
46,195 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-12-10 |
4 |
AS |
$95.00 |
$190,000 |
I/I |
(2,000) |
43,195 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-12-10 |
4 |
OE |
$12.99 |
$25,980 |
I/I |
2,000 |
45,195 |
|
- |
|
1335 Records found
|
|
Page 1 of 54 |
|
|